Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA’s Decision To Back Off Korlym REMS Shows Context Is King

Sep 01 2012

Related Content

Oncology Has Different Risk Management Standards, FDA’s Pazdur Acknowledges

Jun 13 2011

REMS For <em>Qsymia</em> Limits Distribution, But Vivus To Explore Expanding Access

Jul 23 2012

Narrower Indication, New Studies Are Likely Riffs For Jazz Fibromyalgia Drug

Oct 18 2010

Two REMS, Two Names, One Drug: Is It Safe? FDA Questions Jazz's Proposal For Fibromyalgia Indication

Aug 18 2010

<i>Egrifta</i> Approval: FDA Balanced Modest Efficacy, Off-Label Use Potential With Unmet Medical Need

Feb 01 2011

Related Companies

Corcept Therapeutics Incorporated

Genentech, Inc.

Vivus, Inc.

Gilead Sciences, Inc.

Amgen, Inc.

Theratechnologies Inc.

Jazz Pharmaceuticals plc

Additional Topics

Risk Management BioPharmaceutical

More from Drug Safety

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window